CX-4945

CX-4945 is a potent, orally bioavailable inhibitor of casein kinase 2 (CK2, Ki = 0.38 nM) that competes with ATP by filling the small ATP binding site on the catalytic CK2alpha subunit, conferring selectivity. It inhibits proliferation in a panel of cancer cell lines that overexpress CK2 and prevents tumor growth of breast and pancreatic cancer cell xenografts in mice. CX-4945 blocks survival and induces apoptosis in cancer stem cells and is effective against glioblastomas and acute myeloid leukemia cells. CX-4945 also inhibits Cdc2-like kinases (Clk, IC50s = 82.3, 3.8, and 90 nM for Clk1, Clk2, and Clk3, respectively), interfering with alternative splicing.Formal Name: 5-[(3-chlorophenyl)amino]-benzo[c]-2,6-naphthyridine-8-carboxylic acid. CAS Number: 1009820-21-6. Synonyms: Silmitasertib. Molecular Formula: C19H12ClN3O2. Formula Weight: 349.8. Purity: >98%. Formulation: (Request formulation change), A crystalline solid. Solubility: DMF: 20 mg/ml, DMF:PBS(pH 7.2)(1:1): 0.5 mg/ml, DMSO: 15 mg/ml. lambdamax: 209, 240, 260, 360 nm. SMILES: OC(C1=CC2=NC(NC3=CC(Cl)=CC=C3)=C(C=CN=C4)C4=C2C=C1)=O. InChi Code: InChI=1S/C19H12ClN3O2/c20-12-2-1-3-13(9-12)22-18-15-6-7-21-10-16(15)14-5-4-11(19(24)25)8-17(14)23-18/h1-10H,(H,22,23)(H,24,25). InChi Key: MUOKSQABCJCOPU-UHFFFAOYSA-N.